Related Experiment Video

Updated: May 27, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Glucocorticoid resistance in paediatric acute lymphoblastic leukaemia

Vivek A Bhadri1, Toby N Trahair, Richard B Lock

  • 1Centre for Children's Cancer and Blood Disorders, Sydney Children's Hospital, Randwick, NSW 2031, Australia. vbhadri@ccia.unsw.edu.au

Journal of Paediatrics and Child Health
|November 5, 2011
PubMed

Insights

Glucocorticoid resistance impacts outcomes in acute lymphoblastic leukaemia (ALL). This review explores mechanisms of glucocorticoid resistance and therapeutic strategies to improve treatment effectiveness in ALL patients.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Glucocorticoids (GCs) are vital in treating acute lymphoblastic leukaemia (ALL).
  • GC resistance affects approximately 10% of pediatric ALL patients, leading to poorer outcomes.
  • Understanding GC resistance mechanisms is crucial for improving ALL treatment.

Purpose of the Study:

  • To review current knowledge on glucocorticoid resistance in ALL.
  • To discuss the molecular mechanisms underlying GC resistance.
  • To explore therapeutic strategies to overcome GC resistance in ALL.

Main Methods:

  • Literature review of studies on GC resistance in ALL.
  • Analysis of the roles of the GC receptor and co-chaperone molecules.
  • Examination of B-cell lymphoma 2 family members and non-apoptotic cell death pathways.

Main Results:

  • GC resistance involves complex molecular pathways.
  • The GC receptor, co-chaperones, and BCL2 family proteins are implicated.
  • Alternative cell death mechanisms contribute to GC resistance in ALL.

Conclusions:

  • GC resistance is a significant challenge in ALL treatment.
  • Targeting identified molecular pathways may overcome GC resistance.
  • Further research into therapeutic interventions is warranted to improve ALL patient outcomes.

More Related Videos

Modeling Chemotherapy Resistant Leukemia In Vitro08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line12:58

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Published on: May 10, 2017

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...